Table of Contents
- Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- To provide an overview of the global Alzheimer's disease market
- To analyze and forecast the global Alzheimer's disease market size
- To identify key drivers, restraints, opportunities, and challenges in the global Alzheimer's disease market
- Research Methodology
- Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
- Chapter 3. Alzheimer’s Disease Market: By Drug Class Market Trends, Size, and Future Outlook
- By Drug Class Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Drug Class Definitions, Technology Landscape
- By Drug Class Market Drivers
- Product Launches
- Technology Launches
- Increasing prevalence of Alzheimer's disease
- By Drug Class Market Restraints
- High cost of drugs
- Failure of clinical trials
- Chapter 4. Alzheimer’s Disease Market: By Route of Administration Market Trends, Size, and Future Outlook
- By Route of Administration Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Route of Administration Definitions, Technology Landscape
- By Route of Administration Market Drivers
- Rising demand for self-administration
- Increasing geriatric population
- By Route of Administration Market Restraints
- Low patient compliance
- Preference for oral route
- Chapter 5. Alzheimer’s Disease Market: By Distribution Channel Market Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- Increasing online pharmacy sales
- Rising hospital pharmacies demand
- By Distribution Channel Market Restraints
- Preference for retail pharmacies
- Accessibility issues in emerging markets
- Chapter 6. Alzheimer’s Disease Market: By Stage of Disease Market Trends, Size, and Future Outlook
- By Stage of Disease Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Stage of Disease Definitions, Technology Landscape
- By Stage of Disease Market Drivers
- Increasing diagnosis rates
- Growing awareness about early diagnosis
- By Stage of Disease Market Restraints
- High costs of diagnosis
- Lack of biomarkers
- Chapter 7. Alzheimer’s Disease Market: By End User Market Trends, Size, and Future Outlook
- By End User Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By End User Definitions, Technology Landscape
- By End User Market Drivers
- Rising healthcare expenditure
- Increasing demand from hospitals
- By End User Market Restraints
- Limited access in emerging markets
- Preference for homecare settings
- Chapter 8. Alzheimer’s Disease Market: Regional Market Trends, Size, and Future Outlook
- North America Market Size (US$), CAGR (%), and Forecast (2022-2030)
- North America Definitions, Technology Landscape
- North America Market Drivers
- High diagnosis rates
- Favorable reimbursements
- North America Market Restraints
- Patent expirations
- Europe Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Europe Definitions, Technology Landscape
- Europe Market Drivers
- Large geriatric population
- Rising clinical trials
- Europe Market Restraints
- Stringent regulations
- Asia Pacific Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Asia Pacific Definitions, Technology Landscape
- Asia Pacific Market Drivers
- Large patient pool
- Improving healthcare infrastructure
- Asia Pacific Market Restraints
- Low awareness
- Limited access to diagnosis
- Chapter 9. Alzheimer’s Disease Market: Competitive Landscape
- Biogen
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- Eli Lilly
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- Roche
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- Novartis
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- Pfizer
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- Merck & Co.
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- AstraZeneca
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- Johnson & Johnson
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- AbbVie
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- Amgen
- Company Overview
- Financial Overlook
- Product Portfolio
- Strategies
- Biogen
- Chapter 10: Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
- Chapter 11: Appendix
- About Us
Frequently Asked Questions
The current market size of Alzheimer's disease in 2023 is US$ 31.5 billion.
Rising prevalence due to aging populations, Advances in diagnostics and imaging, Emerging pipeline disease-modifying therapies
High drug development costs, low success rates in trials, reimbursement challenges, stigma associated with Alzheimer's, lack of validated biomarkers, misdiagnosis, side effects of drugs, poor adherence, long regulatory timelines, ethical concerns, and alternate treatment preferences
The leading component segment in the Alzheimer’s Disease Market is the cholinesterase inhibitors (used to improve cognition and memory)
Biogen, Eli Lilly, Roche, Novartis, Pfizer, Merck & Co., AstraZeneca, Johnson & Johnson, AbbVie, Amgen
The Alzheimer’s disease market is projected to grow at a CAGR of 8% from US$ 31.5 billion in 2023 to US$ 54 billion by 2030
The key drivers are rising prevalence due to aging populations, advances in diagnostics and imaging techniques, emerging pipeline disease-modifying therapies, increased R&D investments, growing public awareness, government funding for Alzheimer’s care, and favorable regulatory initiatives.